Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Nutr ; 148(1): 70-76, 2018 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-29378037

RESUMO

Background: The frequent consumption of green tea has been shown to have antioxidant and anti-inflammatory effects and to reduce the risk of lung cancer and type 2 diabetes. However, few studies have investigated the relation between green tea consumption and the risk of chronic obstructive lung disease (COPD). Objective: This study aimed to examine the association between green tea intake and COPD with the use of a nationwide representative database. Methods: This study was designed as a cross-sectional survey with the use of data from the Korean National Health and Nutritional Examination Survey collected between 2008 and 2015. Of these participants, 13,570 participants aged ≥40 y were included in the study population. COPD was defined as forced expiratory volume in 1 s (FEV1) divided by forced vital capacity (FVC) <0.70. Multiple linear and logistic regression models were used to examine the association between the frequency of green tea intake and risk of COPD after adjusting for age, sex, body mass index, smoking status, alcohol consumption, physical activity, and socioeconomic status. Results: The incidence of COPD decreased from 14.1% to 5.9% with increased frequency of green tea intake from never to ≥2 times/d (P < 0.001). In the fully adjusted multiple linear regression model, the frequency of green tea intake showed a linear dose-response relation with FEV1/FVC (P-trend = 0.031). In the multiple logistic regression model, the OR for COPD among people who consumed green tea ≥2 times/d was 0.62 (95% CI: 0.40, 0.97), compared with those who never drank green tea, after adjusting for all covariates. Conclusion: This study suggests that the consumption of green tea ≥2 times/d is associated with a reduced risk of COPD in Korean populations.


Assuntos
Povo Asiático , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Chá/química , Adulto , Índice de Massa Corporal , Estudos Transversais , Dieta , Feminino , Volume Expiratório Forçado , Humanos , Incidência , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Inquéritos Nutricionais , Fatores de Risco , Fatores Socioeconômicos , Inquéritos e Questionários , Capacidade Vital
2.
J Altern Complement Med ; 14(9): 1131-6, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18991516

RESUMO

OBJECTIVE: The aim of this study was to investigate the influence of herbal medicine (HM) prescribed by doctors of Korean medicine (KMD) on liver function in Korea. DESIGN AND INTERVENTIONS: For this multicenter, prospective, observational study, we enrolled patients who wished to take HM prescribed by KMD for various medical purposes in Korea. One hundred and twenty-two (122) patients took HM for an average of 20.6 +/- 8.4 (mean +/- standard deviation) days, and completed questionnaires. OUTCOME MEASURES: Liver function tests (LFTs) were performed before (first test) and after each HM treatment (second test). For LFT, aspartate aminotransferase, alanine aminotransferase, total bilirubin (t-Bil), direct bilirubin, alkaline phosphatase, and gamma-glutamyl transferase were measured. RESULTS: There were no significant changes in LFT data between the first and second tests, except in the t-Bil level. However, all data of total bilirubin level in second test were within normal range, except only one patient. Multivariate analysis did not identify any herb that significantly increased t-Bil; hence no hepatotoxic herb was found. Twenty-one (21) of the 122 patients were abnormal on first testing, and 10 at the second testing. Of the patients taking herbs, 4 changed from normal to abnormal and 15 from abnormal to normal (p = 0.019). CONCLUSION: The current study showed that ingestion of HM prescribed by KMD did not increase the frequency of abnormal LFTs, at least in the short term.


Assuntos
Hepatopatias/tratamento farmacológico , Hepatopatias/fisiopatologia , Fígado/fisiopatologia , Fitoterapia/métodos , Extratos Vegetais/uso terapêutico , Adulto , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Aspartato Aminotransferases/sangue , Bilirrubina/sangue , Feminino , Humanos , Coreia (Geográfico) , Fígado/efeitos dos fármacos , Hepatopatias/sangue , Hepatopatias/diagnóstico , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento , gama-Glutamiltransferase/sangue
3.
Schizophr Res ; 103(1-3): 201-8, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18541413

RESUMO

PDGFRB is located on chromosome 5q31-q32, a chromosomal region identified by linkage analyses to contain a susceptibility gene for schizophrenia (SCZ). Recent research has focused on the role of the N-methyl-d-aspartate (NMDA) receptor in the pathogenesis of SCZ. D4 dopamine receptor-mediated transactivation of the gene encoding platelet-derived growth factor receptor beta (PDGFRB) has immediate effects on synaptic neurotransmission via calcium-dependent inactivation of NMDA receptors. In this study, we investigate the association between the PDGFRB gene and SCZ in a Korean population. We screened 6 single-nucleotide polymorphisms (SNPs) in the 5'-upstream region of PDGFRB and conducted a case-control study of 381 SCZ patients and 752 controls. The genotype and haplotype frequencies of 3 of the 6 SNPs [SNP1 (g.-1924T>C, rs3756314), SNP3 (g.-1772A>G, rs3756312) and SNP4 (rs3756311, g.-1658G>A)] were significantly associated with SCZ [SNP1, corrected p=0.012 (co-dominant model), 0.002 (Dominant model), and 0.506 (Recessive model); SNP3 and 4, corrected p=0.003, 0.009, and 0.049]. Haplotype analysis also revealed that ht1 (CGG) and ht2 (TAA) were significantly associated with SCZ (ht1, corrected p=0.018, 0.340, and 0.010; ht2, corrected p=0.002, 0.009, and 0.016). Transient transfection in neuronal cells revealed that ht1 had higher luciferase activity than the vector alone. Furthermore, Pdgfrb expression was increased in the frontal cortex and hippocampus in a mouse model of SCZ induced by MK801. We conclude that SNPs of the 5'-upstream region of PDGFRB are associated with SCZ in a Korean population. These are weak positives that require future studies to confirm these results.


Assuntos
Polimorfismo de Nucleotídeo Único/genética , Receptor beta de Fator de Crescimento Derivado de Plaquetas/genética , Esquizofrenia/genética , Adulto , Animais , Estudos de Casos e Controles , Cromossomos Humanos Par 5/genética , Modelos Animais de Doenças , Feminino , Lobo Frontal/patologia , Frequência do Gene/genética , Predisposição Genética para Doença/genética , Genótipo , Haplótipos , Hipocampo/patologia , Humanos , Coreia (Geográfico) , Masculino , Camundongos , Camundongos Endogâmicos ICR , Pessoa de Meia-Idade
4.
J Pharm Pharmacol ; 57(5): 607-15, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15901350

RESUMO

The anti-inflammatory effects of the methanol extract of the roots of Morinda officinalis (MEMO) (Rubiaceae) were evaluated in-vitro and in-vivo. The effects of MEMO on lipopolysaccharide (LPS)induced responses in the murine macrophage cell line RAW 264.7 were examined. MEMO potently inhibited the production of nitric oxide (NO), prostaglandin E2 and tumour necrosis factor-alpha (TNF-alpha) in LPS-stimulated RAW 264.7 macrophages. Consistent with these results, the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at the protein level, and of iNOS, COX-2 and TNF-alpha at the mRNA level, was also inhibited by MEMO in a concentration-dependent manner. Furthermore, MEMO inhibited the nuclear factor kappa B (NF-kappaB) activation induced by LPS, and this was associated with the prevention of degradation of the inhibitor kappaB (IkappaB), and subsequently with attenuated p65 protein in the nucleus. The anti-inflammatory effect of MEMO was examined in rats using the carrageenan-induced oedema model. The antinociceptive effects of MEMO were assessed in mice using the acetic acid-induced abdominal constriction test and the hot-plate test. MEMO (100, 200 mg kg-1 per day, p.o.) exhibited anti-inflammatory and antinociceptive effects in these animal models. Taken together, the data demonstrate that MEMO has anti-inflammatory and antinociceptive activity, inhibiting iNOS, COX-2 and TNF-alpha expression by down-regulating NF-kappaB binding activity.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Edema/tratamento farmacológico , Macrófagos/efeitos dos fármacos , Morinda/química , Dor/tratamento farmacológico , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Proteínas de Ligação ao Cálcio/metabolismo , Linhagem Celular , Núcleo Celular/efeitos dos fármacos , Núcleo Celular/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Proteínas de Ligação a DNA/metabolismo , Dinoprostona/biossíntese , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Lipopolissacarídeos/farmacologia , Macrófagos/metabolismo , Masculino , Glicoproteínas de Membrana/metabolismo , Metanol/química , Camundongos , Camundongos Endogâmicos ICR , NF-kappa B/metabolismo , Proteínas do Tecido Nervoso/metabolismo , Óxido Nítrico/biossíntese , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Raízes de Plantas/química , RNA Mensageiro/metabolismo , Sinaptotagmina I , Sinaptotagminas , Fator de Necrose Tumoral alfa/biossíntese
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA